Comparison · NCT05481216-sae
PLWHIV With COVID-19 Cases vs HIV Seronegative Patients With COVID-19 Controls: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PLWHIV With COVID-19 Cases vs HIV Seronegative Patients With COVID-19 Controls: serious adverse events. Trial comparisons, record NCT05481216-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05481216-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.461 | 0.417 | 0.505 | wilson | |
| Risk in group 2 | 0.209 | 0.186 | 0.234 | wilson | |
| Risk difference, group 1 minus group 2 | 0.252 | 0.202 | 0.302 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.21 | 1.9 | 2.56 | log | |
| Odds ratio, group 1 over group 2 | 3.24 | 2.57 | 4.08 | log | |
| Number needed to harm, for one more participant with a serious adverse event on PLWHIV With COVID-19 Cases than on HIV Seronegative Patients With COVID-19 Controls | 3.97 | 3.31 | 4.96 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PLWHIV With COVID-19 Cases | Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.~COVID-19: Diagnosed with COVID-19 infection~HIV-1 infection: Diagnosed with HIV-1 infection | 224 | 486 | EG000 |
| Group 2 | HIV Seronegative Patients With COVID-19 Controls | Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.~COVID-19: Diagnosed with COVID-19 infection | 231 | 1,106 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline to week 6
Source ClinicalTrials.gov
Trial
- Title
- HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
- NCT number
- NCT05481216
- Phases
- Conditions
- HIV-1-infection, COVID-19
- Interventions
- COVID-19, HIV-1 infection
- Lead sponsor
- NEAT ID Foundation
- Results first posted
- 2025-03-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05481216?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05481216-sae